Skip to main content
Erschienen in: International Journal of Hematology 3/2013

01.03.2013 | Original Article

Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients

verfasst von: Hayati Demiraslan, Mustafa Sevim, Çiğdem Pala, Süleyman Durmaz, Veli Berk, Leylagül Kaynar, Gökhan Metan

Erschienen in: International Journal of Hematology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Stenotrophomonas maltophilia infection is of concern in patients with cancer. Antibiotics active against S. maltophilia are rarely used in the treatment of febrile neutropenia, making it important to identify the factors influencing mortality in cancer patients with S. maltophilia infection. The objective of this study was to analyze the clinical characteristics and outcomes of cancer and hemopathic patients with S. maltophilia infection and assess the factors influencing the mortality. The microbiology laboratory records of Erciyes University, Faculty of Medicine Hospital were reviewed to retrospectively identify patients with S. maltophilia infection between January 2007 and June 2011. A total of 38 patients (25 male, 13 female) were eligible for the study. The median age of the patients was 53 years. The underlying disease was hematological malignancy and disorders in 76.3 % (29 cases), solid tumors in 15.8 % (six cases), aplastic anemia in 7.9 % (three cases), while 18.4 % (seven cases) were hematopoietic stem cell transplantation (HSCT) recipients. An indwelling central venous catheter was used in 32 cases (84.2 %). Twenty-seven patients (71.1 %) were neutropenic at the onset of infection. Nine patients (23.7 %) were receiving corticosteroid therapy. The overall 14-day mortality rate was 50 %. Three of the patients received empirical antibacterial treatment, and three HSCT recipients received trimethoprim–sulfamethoxazole prophylaxis, which is active against S. maltophilia. Severe sepsis (OR 13.24, 95 % confidence interval (CI) 1.62–108.57) and the duration of the treatment (OR 0.73, 95 % CI 0.60–0.90) were related to death based on logistic regression analysis findings. In immunocompromised hematology–oncology patients with severe sepsis, S. maltophilia should be considered as a possible cause of infection, and should be given effective empirical antibiotic treatment immediately; the antimicrobial spectrum may be narrowed according to results of antibiotic susceptibility test.
Literatur
1.
Zurück zum Zitat Maschmeyer G, Göbel UB. Stenotrophomonas maltophilia, and Burkholderia cepacia complex. In: Mandell GL BJ, Dolin R, editors. Principles and practice of ınfectious diseases. Philedelphia: Elsevier; 2010. pp. 2861–8. Maschmeyer G, Göbel UB. Stenotrophomonas maltophilia, and Burkholderia cepacia complex. In: Mandell GL BJ, Dolin R, editors. Principles and practice of ınfectious diseases. Philedelphia: Elsevier; 2010. pp. 2861–8.
2.
Zurück zum Zitat Bollet C, Davin-Regli A, De Micco P. A simple method for selective ısolation of Stenotrophomonas maltophilia from environmental samples. Appl Environ Microbiol. 1995;61(4):1653–4.PubMed Bollet C, Davin-Regli A, De Micco P. A simple method for selective ısolation of Stenotrophomonas maltophilia from environmental samples. Appl Environ Microbiol. 1995;61(4):1653–4.PubMed
3.
Zurück zum Zitat Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–23.PubMedCrossRef Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis. 2009;9(5):312–23.PubMedCrossRef
4.
Zurück zum Zitat Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53.PubMedCrossRef Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect. 2002;45(1):47–53.PubMedCrossRef
5.
Zurück zum Zitat Dufresne J, Vezina G, Levesque RC. Cloning and expression of the ımipenem-hydrolyzing beta-lactamase operon from Pseudomonas maltophilia in Escherichia coli. Antimicrob Agents Chemother. 1988;32(6):819–26.PubMedCrossRef Dufresne J, Vezina G, Levesque RC. Cloning and expression of the ımipenem-hydrolyzing beta-lactamase operon from Pseudomonas maltophilia in Escherichia coli. Antimicrob Agents Chemother. 1988;32(6):819–26.PubMedCrossRef
6.
Zurück zum Zitat Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KV. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006;25(8):522–6.PubMedCrossRef Safdar A, Rodriguez GH, Balakrishnan M, Tarrand JJ, Rolston KV. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006;25(8):522–6.PubMedCrossRef
7.
Zurück zum Zitat Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD, Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect. 2006;64(3):238–43.PubMedCrossRef Meyer E, Schwab F, Gastmeier P, Rueden H, Daschner FD, Jonas D. Stenotrophomonas maltophilia and antibiotic use in German intensive care units: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in German Intensive Care Units). J Hosp Infect. 2006;64(3):238–43.PubMedCrossRef
8.
Zurück zum Zitat Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34(12):1653–6.PubMedCrossRef Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34(12):1653–6.PubMedCrossRef
9.
Zurück zum Zitat Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9):3980–1.PubMedCrossRef Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9):3980–1.PubMedCrossRef
10.
Zurück zum Zitat Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, DiPersio JF, Fraser VJ, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case–control study. Infect Control Hosp Epidemiol. 2003;24(4):269–74.PubMedCrossRef Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, DiPersio JF, Fraser VJ, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case–control study. Infect Control Hosp Epidemiol. 2003;24(4):269–74.PubMedCrossRef
11.
Zurück zum Zitat Lai CH, Wong WW, Chin C, Huang CK, Lin HH, Chen WF, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect. 2006;12(10):986–91.PubMedCrossRef Lai CH, Wong WW, Chin C, Huang CK, Lin HH, Chen WF, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect. 2006;12(10):986–91.PubMedCrossRef
12.
Zurück zum Zitat Metan G, Hayran M, Hascelik G, Uzun O. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J Infect Dis. 2006;38(6–7):527–31.PubMedCrossRef Metan G, Hayran M, Hascelik G, Uzun O. Which patient is a candidate for empirical therapy against Stenotrophomonas maltophilia bacteraemia? An analysis of associated risk factors in a tertiary care hospital. Scand J Infect Dis. 2006;38(6–7):527–31.PubMedCrossRef
13.
Zurück zum Zitat Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol. 2007;26(1):13–20.CrossRef Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol. 2007;26(1):13–20.CrossRef
14.
Zurück zum Zitat Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.PubMedCrossRef Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–32.PubMedCrossRef
15.
Zurück zum Zitat Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol. 2011;22(5):1019–29.PubMedCrossRef Penack O, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol. 2011;22(5):1019–29.PubMedCrossRef
16.
Zurück zum Zitat Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–6.PubMedCrossRef Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–6.PubMedCrossRef
17.
Zurück zum Zitat Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. Plos One. 2011;6(10). Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. Plos One. 2011;6(10).
18.
Zurück zum Zitat Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52(9):3188–94.PubMedCrossRef Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52(9):3188–94.PubMedCrossRef
19.
Zurück zum Zitat De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.PubMedCrossRef De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.PubMedCrossRef
20.
Zurück zum Zitat Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.PubMedCrossRef Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.PubMedCrossRef
21.
Zurück zum Zitat Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.PubMedCrossRef Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.PubMedCrossRef
22.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.PubMedCrossRef
23.
Zurück zum Zitat Institute CaLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard. vol. M7-A7. PA: Wayne; 2006. Institute CaLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard. vol. M7-A7. PA: Wayne; 2006.
24.
Zurück zum Zitat Hosmer DW LS. Logistic regression: variable selection. In: Applied logistic regression. New York: Willey; 2000. Hosmer DW LS. Logistic regression: variable selection. In: Applied logistic regression. New York: Willey; 2000.
25.
Zurück zum Zitat Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41.PubMedCrossRef Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41.PubMedCrossRef
26.
Zurück zum Zitat Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis. 1994;26(2):163–70.PubMedCrossRef Victor MA, Arpi M, Bruun B, Jonsson V, Hansen MM. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis. 1994;26(2):163–70.PubMedCrossRef
27.
Zurück zum Zitat Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45(12):1602–9.PubMedCrossRef Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45(12):1602–9.PubMedCrossRef
28.
Zurück zum Zitat Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–8.PubMedCrossRef Araoka H, Baba M, Yoneyama A. Risk factors for mortality among patients with Stenotrophomonas maltophilia bacteremia in Tokyo, Japan, 1996–2009. Eur J Clin Microbiol Infect Dis. 2010;29(5):605–8.PubMedCrossRef
29.
Zurück zum Zitat Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38(3):211–5.PubMedCrossRef Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38(3):211–5.PubMedCrossRef
30.
Zurück zum Zitat Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006;106(9):1967–73.PubMedCrossRef Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer. 2006;106(9):1967–73.PubMedCrossRef
31.
Zurück zum Zitat Cairo J, Hachem R, Rangaraj G, Granwehr B, Raad I. Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011;17(11):1711–6.PubMedCrossRef Cairo J, Hachem R, Rangaraj G, Granwehr B, Raad I. Predictors of catheter-related gram-negative bacilli bacteraemia among cancer patients. Clin Microbiol Infect. 2011;17(11):1711–6.PubMedCrossRef
32.
Zurück zum Zitat Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–7.PubMedCrossRef Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30(1):195–7.PubMedCrossRef
33.
Zurück zum Zitat Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–8.PubMedCrossRef Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70(2):101–8.PubMedCrossRef
34.
Zurück zum Zitat Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer. 2009;45(14):2462–72.PubMedCrossRef Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer. 2009;45(14):2462–72.PubMedCrossRef
35.
Zurück zum Zitat Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of Stenotrophomonas (Xanthomonas) maltophilia respiratory infection. Semin Respir Crit Care Med. 2000;21(4):349–55.PubMedCrossRef Vartivarian SE, Anaissie EJ, Kiwan EN, Papadakis KA. The clinical spectrum of Stenotrophomonas (Xanthomonas) maltophilia respiratory infection. Semin Respir Crit Care Med. 2000;21(4):349–55.PubMedCrossRef
36.
Zurück zum Zitat Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001;32(Suppl 2):S104–13.PubMedCrossRef Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin Infect Dis. 2001;32(Suppl 2):S104–13.PubMedCrossRef
37.
Zurück zum Zitat Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 2006;56(4):427–36.PubMedCrossRef Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 2006;56(4):427–36.PubMedCrossRef
38.
Zurück zum Zitat Ghannam DE, Rodriguez GH, Adachi J, Chemaly R, Rolston KV, Raad II, et al. Efficacy of inhaled (Ih)-aminoglycosides (AG) and colistin (CL) in cancer patients with ventilator-associated pneumonia (VAP) during 2000–2005. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. San Francisco: K-288. Ghannam DE, Rodriguez GH, Adachi J, Chemaly R, Rolston KV, Raad II, et al. Efficacy of inhaled (Ih)-aminoglycosides (AG) and colistin (CL) in cancer patients with ventilator-associated pneumonia (VAP) during 2000–2005. In: Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006. San Francisco: K-288.
Metadaten
Titel
Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology–oncology patients
verfasst von
Hayati Demiraslan
Mustafa Sevim
Çiğdem Pala
Süleyman Durmaz
Veli Berk
Leylagül Kaynar
Gökhan Metan
Publikationsdatum
01.03.2013
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2013
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1296-x

Weitere Artikel der Ausgabe 3/2013

International Journal of Hematology 3/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.